IOVANCE BIOTHERAPEUTICS, INC. 10-Q

Item 5. Other Information. Nothing to report. ​ ​ 84 Table of Contents Item 6. Exhibits EXHIBIT INDEX ​ Exhibit ​ Description 10.1 Lease Agreement dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc. and ARE-San Francisco No. 63, LLC (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on February 9, 2021). 10.2 ​ Second Amendment dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on February 9, 2021). 10.3 ​ First Amendment dated as of February 8, 2021, by and between Iovance Biotherapeutics, Inc. and Hudson Skyway Landing, LLC (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the Commission on February 9, 2021). 10.4#++* ​ Executive Employment Agreement, effective as of March 15, 2021, by and between Igor Bilinsky, Ph.D. and Iovance Biotherapeutics, Inc. 31.1++ Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer. 31.2++ Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer. 32.1++ Section 1350 Certification of Chief Executive Officer (furnished herewith). 32.2++ Section 1350 Certification of Chief Financial Officer (furnished herewith). 101 The following financial information from the Quarterly Report on Form 10-Q of Iovance Biotherapeutics, Inc. for the quarter ended March 31, 2021, formatted in iXBRL (Inline eXtensible Business Reporting Language): (1) Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020; (2) Condensed Consolidated Statements of Operations for the three months ended March 31, 2021 and 2020; (3) Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2021 and 2020; (4) Condensed Consolidated Statements of Stockholders’ Equity as of March 31, 2021 and December 31, 2020; (5) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020; and (6) Notes to Condensed Consolidated Financial Statements. 104 ​ Cover Page Interactive Data File – the cover page interactive date file does not appear in the Interactive Date File because its XBRL tags are embedded within the Inline XBRL document. ​ ​ # Indicates a management contract or compensatory plan or arrangement. ++ Filed herewith (unless otherwise noted as being furnished herewith). * Certain portions of the Exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. ​ ​ ​ 85 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ Iovance Biotherapeutics, Inc. May 6, 2021 By: /s/ Maria Fardis, Ph.D., M.B.A. Maria Fardis, Ph.D., M.B.A. Chief Executive Officer (Principal Executive Officer) May 6, 2021 By: /s/ Jean-Marc Bellemin Jean-Marc Bellemin Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) ​ ​ 86